Mesothelioma Mesomark Blood Test
MESOSELIOMA MESOMARK BLOOD TEST
The Food and Drug Administration (FDA) approved the MESOMARK assay to help monitor response to treatment in malignant mesothelioma patients. The MESOMARK test signifies the beginning of a new era in monitoring mesothelioma malignancies,” said Dr. W. Jeffrey Allard, vice president and chief scientific officer of Fujirebio Diagnostics.
The MESOMARK Assay test kit was developed to measure levels of a biomarker, mesothelin, in serum. Biomarkers are substances found in higher-than-normal concentrations in the blood, urine or body tissues of patients with certain types of cancers. The test may be used to monitor patients confirmed as having mesothelioma, for recurrence in patients following surgery, or for measuring response to therapies.
“Current diagnostic tests are less than ideal for quantification of changes in tumor volume, which is key to managing the disease,” continued Allard. “As the MESOMARK results correlate with tumor volume*, it provides a much needed tool for monitoring patient status. It is our plan to collect additional data in the future to support the use of the test to detect mesothelioma.”
MESOMARK test are now making it possible – with a simple blood test -to monitor response to treatment and to detect recurrence following treatment. This provides an important head start to patients racing against this aggressive cancer. “The Meso Foundation is the national research funding, patient support and advocacy organization dedicated to eradicating mesothelioma as a life-threatening disease.
Those wishing to take part in MESOMARK testing will be asked to provide one or more samples of blood. The blood samples will then be sent to a national reference laboratory for testing. In conjunction with other clinical and laboratory data obtained by your doctor, decisions regarding your treatment and care may be simplified. You may discontinue testing at any time.